Rodino-Klapac Louise 4
4 · Sarepta Therapeutics, Inc. · Filed Mar 10, 2025
Insider Transaction Report
Form 4
Rodino-Klapac Louise
President, R&D and Tech Ops
Transactions
- Exercise/Conversion
Common Stock
2025-03-06+17,500→ 82,822 total - Exercise/Conversion
Performance Stock Units
2025-03-06−17,500→ 0 total→ Common Stock (17,500 underlying) - Tax Payment
Common Stock
2025-03-07$103.70/sh−7,990$828,563→ 74,318 total - Tax Payment
Common Stock
2025-03-07$103.70/sh−514$53,302→ 82,308 total
Footnotes (3)
- [F1]Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU.
- [F2]Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023.
- [F3]Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 6, 2023.